https://www.selleckchem.com/products/corn-oil.html
004), and remifentanil maintenance (p 0.001). Vasopressor infusion use was significantly higher with propofol (64.9% v . 8.5%, p 0.001). Propofol maintenance and angiotensin-converting enzyme inhibitor/angiotensin II receptor-blocker use were the only variables identified as risk factors for vasopressor use (p 0.001 and p = 0.009). For patients undergoing TAVR with conscious sedation, remifentanil was associated with more hypoxemia while propofol was associated with a higher rate of vasopressor use. For patients undergoi
Like
Comment
Share
